Eric Lander, President and Director of the Broad Institute*
NGS can be challenging – overcome the bottlenecks you face with the help of our single kit solution. We’ve combined the precision of our QIAseq DNA Panels with intuitive bioinformatics tools to create a single unified solution so you can detect low-frequency variants and analyze your NGS data with confidence. QIAseq DNA panels now include subscription licenses for CLC Genomics Workbench and QIAGEN Clinical Insight (QCI)-Interpret for QIAseq software, so you can make the leap from generating data to accumulating insights with greater ease and speed. Learn more here.
BRCA1 and BRCA2
BRCA1 and BRCA2 Plus
Tumor Mutational Burden
QIAseq DNA Panel kits don’t just deliver superior sequencing coverage and a faster workflow — they also provide the tools you need to gain knowledge from results, using QCI-Interpret for QIAseq software. Supporting more than 1000 laboratories and professionals worldwide, the cloud-based QCI platform provides all the capabilities required to transform complex NGS data into insights, in an easy-to-understand sample report.
• Discover novel findings more quickly
• Access comprehensive variant information
• Use tailored workflows for multiple applications
Check out an example report here.
Want to see how our NGS and analysis tools could work in your own lab? Check out these webinars to discover how our experts seamlessly go from sequencing to insights.
Speaker: Jonathan M. Shaffer, M.B.A., Ph.D., Associate Director, NGS Assay Technologies – QIAGEN
Speaker: Prakriti Mudvari, Ph.D., Senior Bioinformatics Scientist – QIAGEN
*Eric Lander, president and director of the Broad Institute (2015, June 24) Researchers to use Google cloud to aid in genome analysis. [Press release]. Retrieved from https://www.computerworld.com/article/2940374/researchers-to-use-google-cloud-to-aid-in-genome-analysis.html
The products mentioned here are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.
Thank you for your interest in QIAGEN’s targeted NGS panels and optimized analysis tools. You will be contacted shortly by one of our application scientists.